TUZISTRA XR CIII
Generic Name and Formulations:
Codeine polistirex 14.7 mg (equivalent to codeine phosphate 20mg), chlorpheniramine polistirex 2.8 mg (equivalent to chlorpheniramine maleate 4mg); per 5mL; ext-rel susp; cherry flavor.
Vernalis Therapeutics, Inc.
Indications for TUZISTRA XR:
Cough and symptoms associated with upper-respiratory allergies or common cold.
Use lowest effective dose for shortest duration. Use accurate measuring device. ≥18yrs: 10mL every 12hrs; max 20mL/24hrs.
<18yrs: not established.
Children <12yrs. Post-op pain management in children <18yrs following tonsillectomy and/or adenoidectomy.
Ultra-rapid metabolism of codeine and other risk factors for life-threatening respiratory depression in children. Risk from concomitant use with benzodiazepines or other CNS depressants.
Risk of respiratory depression and death related to ultra-rapid metabolizers of codeine (esp. children in post-op following tonsillectomy and/or adenoidectomy). Obstructive sleep apnea. Discontinue if respiratory depression occurs. Post-operatively. Compromised respiratory function (eg, pulmonary disease, depressed ventilator function). Abuse potential (monitor). Avoid in head injury, other intracranial lesions or pre-existing increase in intracranial pressure. Underlying intestinal motility disorders. Acute abdomen. Asthma. Persistent or chronic cough. Hypothyroidism. Addison’s disease. Prostatic hypertrophy. Urethral stricture. Severe hepatic or renal impairment. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Antitussive + antihistamine.
Increased risk of respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, opioids, antihistamines, antipsychotics, anxiolytics, alcohol); avoid. During or within 14 days of MAOIs, concomitant TCAs: not recommended. Paralytic ileus may occur with anticholinergics. May potentiate phenytoin; monitor. May be affected by CYP2D6 and CYP3A4 inhibitors or inducers.
Nausea, vomiting, constipation, abdominal distension/pain, blurred vision, diplopia, visual disturbances, confusion, dizziness, depression, drowsiness, sedation, headache, euphoria, facial dyskinesia, feeling faint, light-headedness, general feeling of discomfort or illness, excitability, nervousness, agitation, restlessness, somnolence, insomina, dyskinesia, irritability, tremor; respiratory depression.
Neurology Advisor Articles
- Higher Levels of Cholesterol May Protect Men From Parkinson Disease
- Ajovy Injection Approved for Migraine Prevention in Adults
- Chronic Pain May Be Contributor to Suicide
- FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- New 15-Item Dyspnea-ALS-Score Assesses Dyspnea in ALS
- CDC: About One in Five U.S. Adults Have Chronic Pain
- Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies